Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 1.00 |
| ▸ | CNR2 | P34972 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.91 |
| ▸ | MLNR | O43193 | 1/20 | 0.91 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.91 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.91 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.91 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.91 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.91 |
| ▸ | DRD1 | P21728 | 1/20 | 0.91 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386088 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55CYP1A2 | |
| Rimonabant SCHEMBL38637 | 0.95 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55CYP1A2 | |
| Rimonabant SCHEMBL29373177 | 0.95 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55CYP1A2 | |
| SCHEMBL13473902 | 0.94 | CNR1 (0.89) | CNR1CNR2CYP2C9GPR55CYP1A2 | |
| Rimonabant SCHEMBL29835931 | 0.94 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55CYP1A2 | |
| Rimonabant SCHEMBL1186698 | 0.94 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55CYP1A2 | |
| SCHEMBL12053639 | 0.94 | CNR1 (0.98) | CNR1CNR2CYP2C9GPR55CYP1A2 | |
| Rimonabant SCHEMBL746112 | 0.93 | CNR1 (0.96) | CNR1CNR2CYP2C9GPR55CYP1A2 | |
| SCHEMBL14397516 | 0.93 | CNR1 (0.92) | CNR1CNR2CYP2C9GPR55CYP1A2 | |
| Rimonabant SCHEMBL8742390 | 0.92 | CNR1 (0.94) | CNR1CNR2CYP2C9GPR55CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618987-A1 | METHODS FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE BY MODULATING OR INHIBITING CANNABINOID RECEPTOR 1 | Joyboy The Igwe L.L.C. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024129891-A1 | METHODS FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE BY MODULATING OR INHIBITING CANNABINOID RECEPTOR 1 | JOYBOY THE IGWE L.L.C. (US) | 2024-06-20 | — | — | WO | claimed |
| EP-2739262-B1 | USE OF A CB1 RECEPTOR ANTAGONIST AS A WHITENING AND/OR ANTI-BROWNING AGENT FOR KERATIN MATERIAL | OREAL (FR) | 2017-09-27 | — | — | EP | claimed |
| US-9662320-B2 | Antagonists of the cannabinoid receptor CB1 for use in the treatment of diseases associated with neuronal dendritic abnormalities | UNIVERSITAT POMPEU FABRA (ES) | 2017-05-30 | — | — | US | claimed |
| US-20160067235-A1 | Antagonists of the Cannabinoid Receptor CB1 for Use in the Treatment of Diseases Associated with Neuronal Dendritic Abnormalities | UNIVERSITAT POMPEU FABRA (ES) | 2016-03-10 | — | — | US | claimed |
| EP-2451794-B1 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTIC BIO AB (SE) | 2016-01-27 | — | — | EP | claimed |
| EP-2739262-A2 | USE OF A CB1 RECEPTOR ANTAGONIST AS A WHITENING AND/OR ANTI-BROWNING AGENT FOR KERATIN MATERIAL | L'OREAL (FR) | 2014-06-11 | — | — | EP | claimed |
| US-20140142106-A1 | METHOD FOR TREATING PERITONEAL FIBROSIS | TAIPEI VETERANS GENERAL HOSPITAL (TW) | 2014-05-22 | — | — | US | claimed |
| WO-2013021129-A2 | USE OF A CB1 RECEPTOR ANTAGONIST AS A WHITENING AND/OR ANTI-BROWNING AGENT FOR KERATIN MATERIAL | L'OREAL (FR) | 2013-02-14 | — | — | WO | claimed |
| EP-2084127-A1 | DIARYL, DIPYRIDINYL AND ARYL-PYRIDINYL DERIVATIVES AND USES THEREOF | Pfizer Products Inc. (US) | 2009-08-05 | — | — | EP | claimed |
| WO-2007017125-A1 | CB1 ANTAGONISTS OR INVERSE ANTAGONISTS AS THERAPEUTICAL AGENTS FOR THE TREATMENT OF INFLAMMATION INVOLVING GENE EXPRESSION | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-02-15 | — | — | WO | claimed |
| EP-1752149-A1 | CB1 Antagonists or inverse agonists as therapeutical agents for the treatment of inflammation involving gene expression | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-02-14 | — | — | EP | claimed |
| EP-1736775-A1 | NOVEL LIGAND OF G PROTEIN COUPLED RECEPTOR PROTEIN AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-12-27 | — | — | EP | claimed |
| US-20060270655-A1 | Combination therapy for treating obesity or maintaining weight loss | SWICK ANDREW G | 2006-11-30 | — | — | US | claimed |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2006-07-20 | — | — | US | claimed |
| US-20060100205-A1 | Compositions for affecting weight loss | U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2006-05-11 | — | — | US | claimed |
| US-20060058293-A1 | Combination of bupropion and a second compound for affecting weight loss | U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2006-03-16 | — | — | US | claimed |
| WO-2006017504-A1 | COMBINATION OF BUPROPION AND A SECOND COMPOUND FOR AFFECTING WEIGHT LOSS | OREXIGEN THERAPEUTICS, INC. (US) | 2006-02-16 | — | — | WO | claimed |
| WO-2005107806-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | OREXIGEN THERAPEUTICS, INC. (US) | 2005-11-17 | — | — | WO | claimed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100205-A1 | Compositions for affecting weight loss | OPRL1, CNR2, OPRK1 | CNR1 4/4885CNR2 2/4885CYP2C9 3242/4885 |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | CNR2, CNR1, PTGS2 | CNR1 2/4885CNR2 1/4885CYP2C9 1016/4885 |
| US-20060058293-A1 | Combination of bupropion and a second compound for affecting weight loss | MC4R, MC3R, MC5R | CNR1 24/4885CNR2 18/4885CYP2C9 3542/4885 |
| US-20160067235-A1 | Antagonists of the Cannabinoid Receptor CB1 for Use in the Treatment of Diseases Associated with Neuronal Dendritic Abnormalities | CNR1, CNR2, DBN1 | CNR1 1/4885CNR2 2/4885CYP2C9 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.